Treatment of Femoropopliteal Artery Disease with Polymer-Coated Drug-Eluting Stent: 5-Year Results of a Prospective, Non-Randomized Study Including the Halo Phenomenon

[1] Bisdas T(2016)CRITISCH Collaborators Endovascular. therapy versus bypass surgery as first-line treatment strategies for critical limb ischemia: results of the interim analysis of the CRITISCH registry J Am Coll Cardiol Intv 24 2557-2565

[2] Borowski M(2022)Surgery or endovascular therapy for chronic limb-threatening ischemia N Engl J Med 25 2305-2316

[3] Stavroulakis K(2016)Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document Eur Heart J 14 1096-1103

[4] Torsello G(2021)2-Year outcomes of the eluvia drug-eluting stent for the treatment of complex femoropopliteal lesions J Am Coll Cardiol Intv 6 692-701

[5] Farber A(2022)Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: primary results of the EMINENT randomized trial Circ 21 1564-1576

[6] Menard MT(2021)Two-Year efficacy and safety results from the IMPERIAL randomized study of the eluvia polymer-coated drug-eluting stent and the zilver PTX polymer-free drug-coated stent Cardiovasc Intervent Radiol 44 368-375

[7] Conte MS(2021)Aneurysmal degeneration of fluoropolymer-coated paclitaxel-eluting stent in the superficial femoral artery: a rising concern CVIR Endovasc 1 56-966

[8] Cortese B(2018)1-year all-comers analysis of the eluvia drug-eluting stent for long femoropopliteal lesions after suboptimal angioplasty J Am Coll Cardiol Intv 11 957-E220

[9] Granada JF(2014)Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications Catheter Cardiovasc Interv 6 E212-638

[10] Scheller B(2022)1-Year outcomes of fluoropolymer-based drug- eluting stent in femoropopliteal practice: predictors of restenosis and aneurysmal degeneration J Am Coll Cardiol Intv 6 630-272

[1] Bisdas T(2016)CRITISCH Collaborators Endovascular. therapy versus bypass surgery as first-line treatment strategies for critical limb ischemia: results of the interim analysis of the CRITISCH registry J Am Coll Cardiol Intv 24 2557-2565

[2] Borowski M(2022)Surgery or endovascular therapy for chronic limb-threatening ischemia N Engl J Med 25 2305-2316

[3] Stavroulakis K(2016)Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document Eur Heart J 14 1096-1103

[4] Torsello G(2021)2-Year outcomes of the eluvia drug-eluting stent for the treatment of complex femoropopliteal lesions J Am Coll Cardiol Intv 6 692-701

[5] Farber A(2022)Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: primary results of the EMINENT randomized trial Circ 21 1564-1576

[6] Menard MT(2021)Two-Year efficacy and safety results from the IMPERIAL randomized study of the eluvia polymer-coated drug-eluting stent and the zilver PTX polymer-free drug-coated stent Cardiovasc Intervent Radiol 44 368-375

[7] Conte MS(2021)Aneurysmal degeneration of fluoropolymer-coated paclitaxel-eluting stent in the superficial femoral artery: a rising concern CVIR Endovasc 1 56-966

[8] Cortese B(2018)1-year all-comers analysis of the eluvia drug-eluting stent for long femoropopliteal lesions after suboptimal angioplasty J Am Coll Cardiol Intv 11 957-E220

[9] Granada JF(2014)Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications Catheter Cardiovasc Interv 6 E212-638

[10] Scheller B(2022)1-Year outcomes of fluoropolymer-based drug- eluting stent in femoropopliteal practice: predictors of restenosis and aneurysmal degeneration J Am Coll Cardiol Intv 6 630-272